Review of bortezomib treatment of antibody-mediated rejection in renal transplantation

Antioxidants and Redox Signaling

Volumn 21, Issue 17, 2014, Pages 2401-2418

  Ejaz, Nicole S ^a   Alloway, Rita R ^b   Halleck, Fabian ^c   Dürr, Michael ^c   Budde, Klemens ^c   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN; IXAZOMIB CITRATE; PROTEASOME; RITUXIMAB; SALINOSPORAMIDE A; ALLOANTIBODY; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; B LYMPHOCYTE; CYTOLOGY; DISEASE CLASSIFICATION; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; IMMUNOADSORPTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PLASMA CELL; PLASMAPHERESIS; REVIEW; GRAFT REJECTION; IMMUNOLOGY;

BORONIC ACIDS; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PYRAZINES;

EID: 84912564359     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5892     Document Type: Review

References (89)

1. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29: 3-9, 2003.
2. Ahmed T and Senzel L. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection. J Clin Apher 27: 173-177, 2012.
3. Allen NH, Dyer P, Geoghegan T, Harris K, Lee HA, and Slapak M. Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation 35: 425-428, 1983.
4. Archdeacon P, Chan M, Neuland C, Velidedeoglu E, Meyer J, Tracy L, Cavaille-Coll M, Bala S, Hernandez A, and Albrecht R. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 11: 896-906, 2011.
5. Ashton-Chess J, Mai HL, Jovanovic V, Renaudin K, Foucher Y, Giral M, Moreau A, Dugast E, Mengel M, Racapé M, Danger R, Usal C, Smit H, Guillet M, Gwinner W, Le Berre L, Dantal J, Soulillou JP, and Brouard S. Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney Int 77: 880-890, 2010.
6. Basler M, Dajee M, Moll C, Groettrup M, and Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 185: 634-641, 2010.
7. Becker YT, Becker BN, Pirsch JD, and Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4: 996-1001, 2004.
8. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, and Cenci S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113: 3040-3049, 2009.
9. Böhmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, Soliman T, Bauer P, Müllner M, and Druml W. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 7: 117-121, 2007.
10. Bonomini V, Vangelista A, Frascà GM, Di Felice A, and Liviano D'Arcangelo G. Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs 31: 698-703, 1985.
11. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2: 1103-1108, 2001.
12. Clynes RA, Towers TL, Presta LG, and Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446, 2000.
13. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 18: 1046-1056, 2007.
14. Colvin RB. Pathology of chronic humoral rejection. Contrib Nephrol 162: 75-86, 2009.
15. Colvin RB and Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immuno 5: 807-817, 2005.
16. Dal Porto JM, Haberman AM, Shlomchik MJ, and Kelsoe G. Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J Immunol 161: 5373-5381, 1998.
17. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway RR, Tevar A, and Woodle ES. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 9: 1063-1071, 2009.
18. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, and Woodle ES. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 41: 105-107, 2009.
19. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, and Woodle ES. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 86: 1754-1761, 2008.
20. Everly MJ, Terasaki PI, Hopfield J, Trivedi HL, and Kaneku H. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation 90: 1493-1498, 2010.
21. Everly MJ, Terasaki PI, and Trivedi HL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 93: 572-577, 2012.
22. Everly JJ, Walsh RC, Alloway RR, and Woodle ES. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Trasplant 14: 662-666, 2009.
23. Flechner SM, Fatica R, Askar M, Stephany BR, Poggio E, Koo A, Banning S, Chiesa-Vottero A, and Srinivas T. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation, 90: 1486-1492, 2010.
24. Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, and Stegall MD. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6: 1841-1847, 2006.
25. Gomez AM, Vrolix K, Martnez-Mart?nez P, Molenaar PC, Phernambucq M, van der Esch E, Duimel H, Verheyen F, Voll RE, Manz RA, De Baets MH, and Losen M. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 186: 2503-2513, 2011.
26. Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, Simpkins CE, Warren DS, Lepley D, Zachary AA, and Kraus ES. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 7: 576-585, 2007.
27. Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M, Daniel C, Wiesener M, Voll RE, and Amann K. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol 120: e47-e58, 2012.
28. Halloran PF, de Freitas DG, Einecke G, Famulski KS, Hidalgo LG, MengeL M, Reeve J, Sellares J, and Sis B. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 10: 2223-2230, 2010.
29. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, and Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127: 165-172, 2004.
30. Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, and Tyan DB. Posttransplant therapy using high-dose human immunoglobulin (intravenous gamaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66: 800-805, 1998.
31. Joudeh A, Saliba KA, Topping KA, and Sis B. Pathologic basis of antibody-mediated organ transplant rejection: from pathogenesis to diagnosis. Curr Opin Organ Transplant 18: 478-485, 2013.
32. Jung T and Grune T. The proteasome and the degradation of oxidized proteins: Part I-structure of proteasomes. Redox Biol 1: 178-182, 2013.
33. Kalim KW, Basler M, Kirk CJ, and Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189: 4182-4193, 2012.
34. Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, and Joosten I. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 12: 341-350, 2012.
35. Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, Pollard V, and Kahan BD. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 23: 63-73, 2009.
36. Kazatchkine MD and Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755, 2001.
37. Kihm LP, Zeier M, and Morath C. Emerging drugs for the treatment of transplant rejection. Expert Opin Emerg Drugs 16: 683-695, 2011.
38. Kim R, Emi M, Tanabe K, and Murakami S. Role of the unfolded protein response in cell death. Apoptosis 11: 5-13, 2006.
39. Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, and Mathew TH. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 32: 164-165, 1981.
40. Kloetzel PM and Ossendorp F. Proteasome and peptidase function in MHC-class I-mediated antigen presentation. Curr Opin Immunol 16: 76-81, 2004.
41. Kuhn DJ, Orlowski RZ, and Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 11: 285-295, 2011.
42. Lederer SR, Friedrich N, Banas B, Welser G, Albert ED, and Sitter T. Effects of mycophenolate mofetil on donorspecific antibody formation in renal transplantation. Clin Transplant 19: 168-174, 2005.
43. Lee PC, Zhu L, Terasaki PI, and Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88: 568-574, 2009.
44. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, and Suberbielle-Boissel C. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibodymediated rejection. Am J Transplant 9: 1099-1107, 2009.
45. Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, Martinez F, Thervet E, Méjean A, Charron D, Duong van Huyen JP, Bruneval P, Legendre C, and Nochy D. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 9: 2561-2570, 2009.
46. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, and Sureshkumar KK. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 12: 579-592, 2011.
47. Luke PP, Scantlebury VP, Jordan ML, Vivas CA, Hakala TR, Jain A, Somani A, Fedorek S, Randhawa P, and Shapiro R. IVIG rescue therapy in renal transplantation. Transplant Proc 33: 1093-1094, 2001.
48. Marfo K, Lu A, Ling M, and Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 6: 922-936, 2011.
49. Mauiyyedi S and Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 11: 609-618, 2002.
50. McConkey DJ and Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11: 164-179, 2008.
51. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, and Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15: 781-787, 2009.
52. Mulley WR, Hudson FJ, Tait BD, Skene AM, Dowling JP, Kerr PG, and Kanellis J. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibodymediated rejection. Transplantation 87: 286-289, 2009.
53. Nagayama Y, Nakahara M, Shimamura M, Horie I, Arima K, and Abiru N. Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice. Clin Exp Immunol 168: 268-273, 2012.
54. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, and Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14: 748-755, 2008.
55. Nimmerjahn F and Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26: 513-533, 2008.
56. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, and Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25: 3892-3901, 2007.
57. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, and Delmonico FL. Plasma exchange and tacrolimusmycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 66: 1460-1464, 1998.
58. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, and Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 9: 201-209, 2009.
59. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, and Palladino MA. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 11: 254-284, 2011.
60. Puttarajappa C, Shapiro R, and Tan HP. Antibody-mediated rejection in kidney transplantation: a review. J Transplant 2012: 193724, 2012.
61. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, and Nickoloff BJ. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293, 2005.
62. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dörner T, and Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6: 741-750, 2006.
63. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, and Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 7: 402-407, 2007.
64. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, and Anderson KC. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005.
65. Roberts DM, Jian SH, and Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation 94: 775-783, 2012.
66. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, and Smith SR. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75: 1490-1495, 2003.
67. Sadaka B, Alloway RR, and Woodle ES. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Invest Drugs 20: 1535-1542, 2011.
68. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R, Rabant M, Pallet N, Nochy D, Anglicheau D, Leruez M, Loupy A, Thervet E, Hermine O, and Legendre C. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 10: 681-686, 2010.
69. Sberro-Soussan R, Zuberl J, Suberbielle-Boissel C, and Legendre C. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year posttreatment. Clin Transpl 2010: 409-414, 2010.
70. Schmidt N, Alloway RR, Walsh RC, Sadaka B, Shields AR, Girnita AL, Hanseman DJ, and Woodle ES. Prospective evaluation of the toxicity profile of proteasome inhibitorbased therapy in renal transplant candidates and recipients. Transplantation 94: 352-361, 2012.
71. Singh N, Pirsch J, and Samaniego M. Antibody mediated rejection: treatment alternatives and outcome. Transplant Rev (Orlando) 23: 34-46, 2009.
72. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, and Valente M. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8: 753-760, 2008.
73. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, and Weening JJ. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7: 518-526, 2007.
74. Stegall MD, Dean PG, and Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 9: 998-1005, 2009.
75. Sureshkumar KK, Hussain SM, Carpenter BJ, Sandroni SE, and Marcus RJ. Antibody-mediated rejection following renal transplantation. Expert Opin Pharmacother 8: 913-921, 2007.
76. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A, Montgomery RA, Nickerson P, Platt JL, Rabb H, Thistlethwaite R, Tyan D, and Delmonico FL. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4: 1033-1041, 2004.
77. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, and Dave SD. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 87: 1555-1561, 2009.
78. Tyden G, Kumlien G, and Efvergren M. Present techniques for antibody removal. Transplantation 84: S27-S29, 2007.
79. Tzvetanov I, Spaggiari M, Joseph J, Jeon H, Thielke J, Oberholzer J, and Benedetti E. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature. Transplant Proc 44: 2971-2975, 2012.
80. Valenzuela NM and Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 1034: 41-70, 2013.
81. Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, and Kaveri SV. Role of natural antibodies in immune homeostatsis: IVIg perspective. Autoimmun Rev 7: 440-444, 2008.
82. Velcade [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc., 2013.
83. Waiser J, Budde K, Schütz M, Liefeldt L, Rudolph B, Schönemann C, Neumayer HH, and Lachmann N. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 27: 1246-1251, 2012.
84. Walsh RC, Brailey P, Girnita A, Alloway RR, Shields AR, Wall GE, Sadaka BH, Cardi M, Tevar A, Govil A, Mogilishetty G, Roy-Chaudhury P, and Woodle ES. Early and late acute antibody-mediated rejection differs immunologically and in response to proteasome inhibition. Transplantation 91: 1218-1226, 2011.
85. Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, and Woodle ES. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89: 277-284, 2010.
86. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 47: 115-123, 2010.
87. Woodle ES, Walsh RC, Alloway RR, Girnita A, and Brailey P. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant 15: 548-556, 2011.
88. Wu J. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2: 904-912, 2002.
89. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, and Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 8: 2607-2617, 2008.